Kevin Dodelande's iMi launches into early cancer detection

Paris, France Sep 27, 2023 (Issuewire.com) - Artificial Intelligence is more than just ChatGPT! Particularly in healthcare. AI, so often demonized, can be a source of virtuous progress. The young French company iMi, founded in 2021 by Kevin Dodelande and Christophe Le Morvan, proves this. By exploiting totally secure, anonymized healthcare data from various databases (ANSM, SNDS, PMIS, and clinical trials), iMi, in partnership with experts, has developed an innovative approach to optimizing early cancer detection protocols. How? Through the collection, comparison, analysis, and correlation of medical data.

Cutting-edge tools to anticipate the future and reduce risks

Through certified scientific projects, iMi develops the scientific exploitation of anonymous and totally secure data from groups of patients from French oncology centers organized in a network (Institut Gustave Roussy, Clermont-Ferrand, Hôpital Pitié Salpétrière, CHU de Rouen...). By cross-referencing and correlating them with other medical databases, iMi creates a health data warehouse. Overall objective? To enable doctors and researchers to detect early warning signals. Using cutting-edge algorithms, the young company takes data analysis to unprecedented levels, developing "predictive modeling" across symptoms to define profiles, pathways, and diagnoses to detect patients before the disease spreads.
Thanks to the talent of its CEO, Christophe Le Morvan, a former data expert at J&J, Pfizer, and GSK, iMi has developed an innovative and concerted approach with its ecosystem to establish and propose detection protocols, notably for lung and colorectal cancers.

Cancer: a race against time

Kevin Dodelande explains: "Cancer is not a disease that appears overnight. It manifests itself through a large number of diffuse symptoms, such as extreme fatigue, which must be investigated through multiple tests before a diagnosis can be made. All this takes time, even years. Unfortunately, even more so when you live in a medical desert. Cancer is a race against time. To start the fight against the disease early enough, iMi and its scientific partners are seeking to concentrate on and analyze patient data (analyses, diagnosis, medical prescriptions, and hospital specialists.) The aim is to speed up the detection and early management of the patient by drawing up an exhaustive list of all the warning signs and effective protocols. The result: a diagnosis detected early enough to avoid "loss of chance" for the patient, and personalized follow-up a fortiori when the patient lives in a rural area.

Early detection of cancer means lower costs for the community

The earlier a cancer is detected, the less it costs the community, adds Kevin Dodelande. "The cost of treating a stage 1 cancer may be 10,000, whereas it costs three times as much when discovered at stage 2, and as much as 100,000 later." In short, solid savings for Social Security, not to mention the well-being of the patient and his or her family!
What's more, when patients return home, they receive personalized care wherever they live.

The same protocol throughout France

"The great strength of our data processing with AI is to ensure that a lung cancer patient in Lille, Limoges, or Narbonne can be detected quickly and, if necessary, receive treatment specific to his or her needs, thanks to a sharing of best medical practices.
To achieve this, iMi uses several open sources, including the SNDS (national health data system), PMSI data, and clinical trial data hosted in the data warehouses of its certified partner. iMi also relies on the network of ARS (regional health agencies) and projects initiated by networked cancer centers.
Artificial intelligence is much talked about. But it's also saving lives. iMi stands out for its expert and technological contributions in the field of predictive medicine. As Kevin Dodelande concludes: "Thanks to our expertise in managing open-source medical data from around the world, I modestly believe that we are helping to make a difference to public health." As technology continues to evolve, iMi's efforts mark only the beginning of a new era in predictive medicine.

Kevin Dodelande

Kevin Dodelande, 31, a specialist in artificial intelligence, is the founder of iMi, a company dedicated to data processing and analysis.

https://medium.com/@kdodelande/kevin-dodelande-management-in-the-age-of-web-3-0-6a38ea4adf28

https://www.digitalpulsehq.com/kevin-dodelande-ai-and-football-team-manager-a-winning-combination/31/08/2023/

https://www.investorworldreview.com/article/651557438-kevin-dodelande-how-data-is-revolutionizing-the-transfer-market

Media Contact

iMi-intelligence

[email protected]

https://imi-intelligence.com